New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 6, 2012
14:53 EDTARRYArray BioPharma to present positive Phase 2 data on ARRY-797
Array BioPharma announced that an abstract discussing the final Phase 2 trial results with ARRY-797 in patients with osteoarthritis pain will be presented at the 2012 American College of Rheumatology Annual Meeting in Washington, D.C. This abstract includes data on ARRY-797's analgesic effect and markers of disease modification. In addition, biomarkers of cartilage (COMP) and bone (CTX I) degradation were assessed. ARRY 797 treatment resulted in statistically significant decreases in COMP and CTX I at week 4 (decreases of 10% and 38% versus placebo, respectively). The decrease in CTX I was sustained and returned to baseline by the follow up visit. The abstract concludes that further evaluation of the potential for disease modifying activity is warranted.
News For ARRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 30, 2015
10:46 EDTARRYLeerink biotech analyst holds an analyst/industry conference call
Biotech Analyst Liang, along with Dr. Alan List an MDS Specialist, provide an update on the myelodysplastic syndrome pipeline on an Analyst/Industry conference call to be held on May 5 at 2:30 pm.
April 27, 2015
12:28 EDTARRYOptions with increasing implied volatility
Options with increasing implied volatility: THRX ARRY AKRX DECK HSBC
April 21, 2015
13:03 EDTARRYLoxo Oncology reports encouraging initial results from study for LOXO-101
Subscribe for More Information
April 20, 2015
07:20 EDTARRYAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use